Ferriprox(deferiprone)
Deferiprone, Ferriprox (deferiprone) is a small molecule pharmaceutical. Deferiprone was first approved as Ferriprox on 1999-08-25. It is used to treat iron overload in the USA. It has been approved in Europe to treat beta-thalassemia and iron overload.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Deferiprone, Ferriprox (discontinued: Ferriprox)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Deferiprone
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| FERRIPROX | Chiesi Farmaceutici | N-021825 RX | 2011-10-14 | 2 products, RLD |
| FERRIPROX | Chiesi Farmaceutici | N-208030 RX | 2015-09-09 | 1 products, RLD, RS |
| FERRIPROX | Chiesi Farmaceutici | N-212269 RX | 2020-05-19 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| deferiprone | ANDA | 2024-05-07 |
| ferriprox | New Drug Application | 2023-07-01 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| iron overload | — | D019190 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
DEFERIPRONE, FERRIPROX, CHIESI | |||
| 2028-04-30 | ODE-417, ODE-418, ODE-419, ODE-420, ODE-421 | ||
| 2024-04-30 | I-859 | ||
HCPCS
No data
Clinical
Clinical Trials
2370 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Beta-thalassemia | D017086 | Orphanet_848 | D56.1 | — | — | — | 1 | — | 1 |
| Thalassemia | D013789 | EFO_1001996 | D56 | — | — | — | 1 | — | 1 |
| Iron overload | D019190 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Nerve degeneration | D009410 | — | — | — | — | — | — | 1 | 1 |
| Pantothenate kinase-associated neurodegeneration | D006211 | — | G23.0 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Deferiprone |
| INN | deferiprone |
| Description | Deferiprone is a member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia. It has a role as an iron chelator and a protective agent. ... More |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1c(O)c(=O)ccn1C |
Identifiers
| PDB | — |
| CAS-ID | 30652-11-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL70927 |
| ChEBI ID | 68554 |
| PubChem CID | 2972 |
| DrugBank | DB08826 |
| UNII ID | 2BTY8KH53L (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 303,759 documents
View more details
Safety
Black-box Warning
Black-box warning for: Deferiprone, Ferriprox
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
7,748 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use